Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension (TRANSIT-1)

Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension

This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral treatment (selexipag) targeting the disease in a similar way. The purpose of the study is i) to investigate the safety and tolerability of oral selexipag in patients who transition from inhaled treprostinil, ii) to investigate the effects of oral selexipag on PAH severity and exercise ability before and after transition, and iii) to gain new information about the patients experience taking oral selexipag compared to inhaled treprostinil. Study participants may stay in the study until the FDA has granted marketing authorization.

Study Overview

• Status: Completed
• Conditions: Pulmonary Arterial Hypertension
• Intervention / Treatment: Drug: Selexipag

• Study Type: Interventional
• Enrollment (Actual): 34
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • La Jolla, California, United States
      • UCSD Medical Center -La Jolla
    • San Francisco, California, United States
      • UCSF Medical Center
    • Torrance, California, United States
      • Harbor Ucla Medical Center
  • Georgia
    • Atlanta, Georgia, United States
      • Emory University
    • Austell, Georgia, United States
      • Piedmont Healthcare Research Institute
  • Kentucky
    • Louisville, Kentucky, United States
      • Kentuckiana Pulmonary Associates
  • Michigan
    • Ann Arbor, Michigan, United States
      • University of Michigan Health System
  • Missouri
    • Saint Louis, Missouri, United States
      • Washington University School of Medicine
  • North Carolina
    • Durham, North Carolina, United States
      • Duke Unversity
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States
      • University of Pennsylvania
    • Pittsburgh, Pennsylvania, United States
      • Allegheny General Hospital
    • Pittsburgh, Pennsylvania, United States
      • University of Pittsburgh Medical Center Health System
  • Texas
    • Dallas, Texas, United States
      • UT Southwestern
    • Houston, Texas, United States
      • Houston Methodist Hospital
  • Virginia
    • Norfolk, Virginia, United States
      • Sentara Cardiovascular Research Instistute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female patients aged from 18 to 75 years (inclusive) with pulmonary arterial hypertension (PAH).
• Etiology of PAH belonging to one of the following subgroups: idiopathic PAH, Heritable PAH, drug or toxin induced, associated with connective tissue disease, associated with HIV infection, associated with congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair.
• Women of childbearing potential are eligible only if the following apply: Negative serum pregnancy test at Visit 1 and a negative urine pregnancy test at Visit on Day 1, agreement to undertake monthly urine pregnancy tests during the study and up to 30 days after study drug discontinuation, agreement to use efficient methods of birth control from Visit 1 up to at least 30 days after study treatment discontinuation.
• Documented hemodynamic diagnosis of PAH by right heart catheterization (RHC).
• Inhaled treprostinil treatment ongoing for at least 90 days and at stable dose for at least 30 days prior to Day 1.
• WHO functional class (FC) II or III at Visit 1 and Visit 2.
• 6-minute walk distance (6MWD) ≥ 300 m at Visit 1.
• On background oral PAH therapy for at least 90 days and on a stable dose for 30 days prior to Visit 2. Acceptable concomitant PAH therapies are one or two of the following: a) Endothelin receptor antagonist (ERA), b) Phosphodiesterase type 5 (PDE-5) inhibitor or soluble guanylate cyclase (sGC) stimulator.

Exclusion Criteria:

• Treatment with any prostacyclin or prostacyclin analogs other than inhaled treprostinil within 90 days before Day 1, or patients scheduled to receive any of these treatments within the duration of the study.
• Any hospitalization within 90 days before Day 1.
• Worsening in WHO FC within 30 days prior to Day 1.
• At any time prior to Day 1, documented moderate or severe obstructive or restrictive lung disease.
• Known or suspicion of pulmonary veno-occlusive disease (PVOD).
• Anemia: < 80 g/L (5.0 mmol/L) hemoglobin.
• Clinically relevant thyroid disease (hypo- or hyperthyroidism).
• Known and documented severe hepatic impairment.
• Uncontrolled hypertension.
• Sitting systolic blood pressure < 85 mmHg.
• Acute myocardial infarction within the last 90 days prior to Visit 1.
• History of left-sided heart disease.
• Left ventricular disease/dysfunction risk factors.
• Documented pericardial effusion within 90 days prior to Visit 1.
• Documented severe renal insufficiency.
• Receiving or having received any investigational drugs within 90 days before Day 1.
• Having received selexipag at any time before Day 1.
• Acute or chronic impairment (other than dyspnea), limiting the ability to comply with study requirements.
• Recently conducted or planned cardio-pulmonary rehabilitation program based on exercise training during the study.
• Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.
• Known concomitant life-threatening disease with a life expectancy < 12 months.
• Females who are lactating or pregnant or plan to become pregnant during the study.
• Known hypersensitivity to any of the excipients of the drug formulation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Selexipag, Open Label; Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily. From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag.

Drug: Selexipag; Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).; Other Names: ACT-293987; Uptravi

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Sustained Treatment Transition	A sustained treatment transition is considered if the 3 following criteria are met a) being on study treatment (selexipag) at Week 16, and b) not having a study treatment interruption(s) of a total of 8 days or more prior to Week 16, and c) absence of inhaled treprostinil or any prostanoid treatment after Week 8 up to Week 16. The percentage of subjects with a sustained treatment transition is calculated with 95% confidence interval (CI) using the Clopper-Pearson method.	At Week 16
Percentage of Subjects With Treatment-emergent Adverse Events (AEs),	Percentage of subjects with treatment-emergent AEs (serious and non serious), regardless of relationship to selexipag	26 weeks on average (from the first dose of selexipag up to 30 days after the last dose of selexipag)
Number of Subjects With Adverse Events Leading to Premature Discontinuation of Selexipag	Number of subjects with adverse events leading to premature discontinuation of selexipag is determined from the first dose of selexipag up to the last dose of selexipag	Up to 22 weeks on average
Absolute Change From Baseline Over Time in Blood Pressure	Both systolic(SBP) and diastolic (DBP) arterial blood pressure were measured in a sitting position after at least 5 minutes of rest at scheduled time points. Median change from baseline to pre-specified post-baseline visits are calculated	Baseline, Week 4, Week 12, Week 16
Absolute Change From Baseline Over Time in Heart Rate (HR)	Pulse rate is measured after at least 5 minutes of rest in a sitting position. Median change from baseline to pre-specified post-baseline visits are calculated.	Baseline, Week 4, Week 12, Week 16
Maximal Tolerated Dose	This is the individual maximal tolerated dose (MTD) observed at Week 12 in the subjects still on selexipag at Week 16. MTD is defined as the dose of selexipag reached with the last dose change up to Week 12	At Week 12, in subjects still on selexipag at Week 16
Time to Discontinuation of Inhaled Treprostinil.	Median time from baseline (Day1) to the end of down-titration of inhaled treprostinil is calculated	Baseline to Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With WHO Functional Class (FC) Change From Baseline	The World Health Organization (WHO) defines 4 classes to classify the functional status of patients with pulmonary hypertension: Class I (FC I): No limitation of physical activity. Class II (FC II): Slight limitation of physical activity. Class III (FC III): Marked limitation of physical activity. Class IV (FC IV): Inability to carry out any physical activity without symptoms. Number of patients with improvement (shift from a higher to a lower class), worsening (shift from a lower to a higher class) or no change in WHO functional class at end of study compared to baseline are determined.	Baseline and Week 16
Absolute Change in 6-minute Walk Distance (6MWD) at Trough	The 6MWT is a non-encouraged test, which measures the distance (in meters) covered by the subject during a 6-minute walk. It is performed in a 30-meters long flat corridor, where the patient is instructed to walk as far as possible, back and forth around two cones, with the permission to slow down, rest, or stop if needed. Absolute change from baseline to Week 16 in 6MWD is measured at trough levels of inhaled treprostinil and/or selexipag. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWT at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWT at Visit 5 (Week 16).	Baseline and Week 16
Percentage of Patients With Change in 6-minute Walk Distance (6MWD)	Percentage of patients with an increase (> 8% of baseline), maintenance (+/- 8% of baseline), or decrease (< -8% of baseline) in their 6MWD (at trough) from baseline to Week 16. The ± 8% boundaries for change in 6MWD reflect the approximately 8% coefficient of variation in the reproducibility of the 6MWD. The trough level of inhaled treprostinil is defined as the last dose having been taken not less than 4 hours and not more than 48 hours prior to the 6MWD test at Visit 1 (screening). The trough level of selexipag was defined as the last dose having been taken not less than 8 hours and not more than 7 days prior to the 6MWD test at Visit 5 (Week 16).	Baseline and Week 16
Geometric Mean of the Ratio in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP) of Week 16 to Baseline	Changes in NT-proBNP levels in plasma are expressed by the geometric mean of the ratio of Week 16 to baseline	Baseline and Week 16

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline to Week 16 in the Treatment Satisfaction Questionnaire for Medication Questionnaire (TSQM II)	The Treatment Satisfaction Questionnaire for Medication, Version II (TSQM II) is a validated tool that evaluate the subject's satisfaction with the study treatment. It includes a total of 11 questions related to satisfaction with treatment effectiveness, side effects,convenience, and global satisfaction. TSQM scores range from 0 to 100 for each domain; a higher score indicates higher satisfaction with treatment.	Baseline and Week 16

Collaborators and Investigators

• Sponsor: Actelion

Publications and helpful links

General Publications

• Frost A, Janmohamed M, Fritz JS, McConnell JW, Poch D, Fortin TA, Miller CE, Chin KM, Fisher M, Eggert M, McEvoy C, Benza RL, Farber HW, Kim NH, Pfister T, Shiraga Y, McLaughlin V. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. J Heart Lung Transplant. 2019 Jan;38(1):43-50. doi: 10.1016/j.healun.2018.09.003. Epub 2018 Sep 12.

Study record dates

Study Major Dates

• Study Start (Actual): October 12, 2015
• Primary Completion (Actual): December 5, 2016
• Study Completion (Actual): December 5, 2016

Study Registration Dates

• First Submitted: June 11, 2015
• First Submitted That Met QC Criteria: June 11, 2015
• First Posted (Estimate): June 15, 2015

Study Record Updates

• Last Update Posted (Actual): January 23, 2018
• Last Update Submitted That Met QC Criteria: December 28, 2017
• Last Verified: December 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension, Pulmonary; Hypertension; Pulmonary Arterial Hypertension; Familial Primary Pulmonary Hypertension; Antihypertensive Agents; Selexipag
• Other Study ID Numbers: AC-065A304